| Year |
Citation |
Score |
| 2021 |
Jeung HC, Delaney R, Aleshin A, Indarte M, Correa RG, Bankston LA, Layng FIAL, Ahmed Z, Wistuba I, Yao Y, Duenas DG, Zhang S, Meuillet EJ, Marassi F, Liddington RC, ... ... Powis G, et al. PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer. Experimental Cell Research. 112930. PMID 34800542 DOI: 10.1016/j.yexcr.2021.112930 |
0.305 |
|
| 2019 |
Maruggi M, Layng FIAL, Lemos R, Garcia G, James BP, Sevilla M, Soldevila F, Baaten BJG, de Jong PR, Koh MY, Powis G. Absence of HIF1A leads to glycogen accumulation and an inflammatory response that enables pancreatic tumor growth. Cancer Research. PMID 31585939 DOI: 10.1158/0008-5472.CAN-18-2994 |
0.303 |
|
| 2019 |
Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zhang S, Lemos R, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, ... ... Powis G, et al. An inhibitor of the pleckstrin homology domain of CNK1 selectively blocks the growth of mutant KRAS cells and tumors. Cancer Research. PMID 31040156 DOI: 10.1158/0008-5472.Can-18-2372 |
0.31 |
|
| 2018 |
Campos AD, James B, Jong PD, Lemos R, Marino N, Powis G. Abstract 2428: Redox regulation of β-catenin in colorectal cancer Cancer Research. 78: 2428-2428. DOI: 10.1158/1538-7445.Am2018-2428 |
0.341 |
|
| 2016 |
Grandjean G, De Jong PR, James BP, Koh MY, Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, Edupuganti R, Devkota A, Stancu G, Liddington RC, Dalby KN, ... Powis G, et al. Definition of a novel feed-forward mechanism for glycolysis-HIF1α signaling in hypoxic tumors highlights adolase A as a therapeutic target. Cancer Research. PMID 27261507 DOI: 10.1158/0008-5472.Can-16-0401 |
0.39 |
|
| 2016 |
Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. PMID 27167191 DOI: 10.18632/Oncotarget.9153 |
0.401 |
|
| 2015 |
Nam S, Chang HR, Jung HR, Gim Y, Kim NY, Grailhe R, Seo HR, Park HS, Balch C, Lee J, Park I, Jung SY, Jeong KC, Powis G, Liang H, et al. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. Cancer Letters. 356: 880-90. PMID 25449779 DOI: 10.1016/J.Canlet.2014.10.038 |
0.358 |
|
| 2015 |
Koh MY, Nguyen V, Lemos R, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Research. 75: 316-29. PMID 25421578 DOI: 10.1158/0008-5472.Can-13-2190 |
0.413 |
|
| 2015 |
Kirkpatrick DL, Indarte M, Scott M, Madrigal A, Grandjean G, Powis G. Abstract 2583: Refinement of inhibitors of the KRAS-signaling naocluster protein, CNKSR1, that block oncogenic KRAS signaling and growth Cancer Research. 75: 2583-2583. DOI: 10.1158/1538-7445.Am2015-2583 |
0.418 |
|
| 2014 |
Nam S, Chang HR, Kim KT, Kook MC, Hong D, Kwon CH, Jung HR, Park HS, Powis G, Liang H, Park T, Kim YH. PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene. 33: 4941-51. PMID 24681952 DOI: 10.1038/Onc.2014.80 |
0.327 |
|
| 2014 |
Chang HR, Nam S, Kook M, Park HS, Jung HR, Gim Y, Liang H, Powis G, Kim YH. Abstract 1781: Identification of focal adhesion and actin cytoskeleton regulation family genes as druggable target for gastric cancer Cancer Research. 74: 1781-1781. DOI: 10.1158/1538-7445.Am2014-1781 |
0.36 |
|
| 2012 |
Koh MY, Powis G. Passing the baton: the HIF switch. Trends in Biochemical Sciences. 37: 364-72. PMID 22818162 DOI: 10.1016/J.Tibs.2012.06.004 |
0.346 |
|
| 2012 |
Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Molecular Cancer Research : McR. 10: 392-400. PMID 22275514 DOI: 10.1158/1541-7786.Mcr-11-0359 |
0.302 |
|
| 2011 |
Kim YH, Coon A, Baker AF, Powis G. Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. Cancer Chemotherapy and Pharmacology. 68: 405-13. PMID 21069338 DOI: 10.1007/S00280-010-1500-0 |
0.76 |
|
| 2011 |
Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. International Journal of Cancer. 128: 787-96. PMID 20473884 DOI: 10.1002/Ijc.25394 |
0.34 |
|
| 2010 |
Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, ... Powis G, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Molecular Cancer Therapeutics. 9: 706-17. PMID 20197390 DOI: 10.1158/1535-7163.Mct-09-0985 |
0.351 |
|
| 2010 |
Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro-Oncology. 12: 559-69. PMID 20156803 DOI: 10.1093/Neuonc/Nop058 |
0.327 |
|
| 2009 |
Koh MY, Spivak-Kroizman TR, Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5945-6. PMID 19789327 DOI: 10.1158/1078-0432.Ccr-09-1650 |
0.339 |
|
| 2009 |
Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Research. 69: 5073-81. PMID 19491272 DOI: 10.1158/0008-5472.Can-08-3839 |
0.317 |
|
| 2007 |
Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Molecular Cancer Therapeutics. 6: 2505-14. PMID 17766839 DOI: 10.1158/1535-7163.MCT-06-0698 |
0.377 |
|
| 2007 |
Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G. The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3388-94. PMID 17545547 DOI: 10.1158/1078-0432.Ccr-06-0873 |
0.764 |
|
| 2006 |
Welsh SJ, Koh MY, Powis G. The hypoxic inducible stress response as a target for cancer drug discovery. Seminars in Oncology. 33: 486-97. PMID 16890803 DOI: 10.1053/j.seminoncol.2006.04.011 |
0.313 |
|
| 2006 |
Engman L, McNaughton M, Gajewska M, Kumar S, Birmingham A, Powis G. Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds. Anti-Cancer Drugs. 17: 539-44. PMID 16702810 DOI: 10.1097/00001813-200606000-00007 |
0.301 |
|
| 2006 |
Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Molecular Pharmacology. 70: 589-603. PMID 16622074 DOI: 10.1124/Mol.106.025007 |
0.33 |
|
| 2006 |
Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Molecular Cancer Therapeutics. 5: 630-6. PMID 16546977 DOI: 10.1158/1535-7163.Mct-05-0487 |
0.36 |
|
| 2006 |
Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL, Powis G. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. The Journal of Laboratory and Clinical Medicine. 147: 83-90. PMID 16459166 DOI: 10.1016/J.Lab.2005.09.001 |
0.34 |
|
| 2005 |
Wipf P, Lynch SM, Powis G, Birmingham A, Englund EE. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system. Organic & Biomolecular Chemistry. 3: 3880-2. PMID 16240002 DOI: 10.1039/B510718K |
0.344 |
|
| 2005 |
Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. Nmr in Biomedicine. 18: 430-9. PMID 16206237 DOI: 10.1002/Nbm.977 |
0.344 |
|
| 2005 |
Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (New York, N.Y.). 7: 475-85. PMID 15967100 DOI: 10.1593/Neo.04628 |
0.311 |
|
| 2004 |
Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncology Research. 14: 513-27. PMID 15559765 DOI: 10.3727/0965040042380487 |
0.774 |
|
| 2004 |
Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Archives of Biochemistry and Biophysics. 429: 123-33. PMID 15313215 DOI: 10.1016/J.Abb.2004.04.020 |
0.773 |
|
| 2004 |
Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Molecular Cancer Therapeutics. 3: 763-72. PMID 15252137 |
0.3 |
|
| 2004 |
Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, Kirkpatrick L, Abraham R, Powis G. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Organic & Biomolecular Chemistry. 2: 1911-20. PMID 15227545 DOI: 10.1039/B405431H |
0.379 |
|
| 2004 |
Mustacich D, Wagner A, Williams R, Bair W, Barbercheck L, Stratton SP, Bhattacharyya AK, Powis G. Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse. Carcinogenesis. 25: 1983-9. PMID 15166090 DOI: 10.1093/Carcin/Bgh195 |
0.758 |
|
| 2004 |
Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics. 3: 233-44. PMID 15026543 |
0.301 |
|
| 2003 |
Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Current Cancer Drug Targets. 3: 391-405. PMID 14683498 |
0.314 |
|
| 2003 |
Engman L, Al-Maharik N, McNaughton M, Birmingham A, Powis G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells. Bioorganic & Medicinal Chemistry. 11: 5091-100. PMID 14604673 DOI: 10.1016/J.Bmc.2003.08.021 |
0.425 |
|
| 2003 |
Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. The Journal of Laboratory and Clinical Medicine. 142: 46-51. PMID 12878985 DOI: 10.1016/S0022-2143(03)00068-4 |
0.394 |
|
| 2003 |
Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Molecular Cancer Research : McR. 1: 682-9. PMID 12861054 |
0.633 |
|
| 2003 |
Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, Jones DP. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. The Journal of Biological Chemistry. 278: 33408-15. PMID 12816947 DOI: 10.1074/Jbc.M211107200 |
0.328 |
|
| 2003 |
Husbeck B, Stringer DE, Gerner EW, Powis G. Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells. Biochemical and Biophysical Research Communications. 306: 469-75. PMID 12804587 DOI: 10.1016/S0006-291X(03)00993-8 |
0.795 |
|
| 2003 |
Meuillet EJ, Mahadevan D, Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski AP, Powis G. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Molecular Cancer Therapeutics. 2: 389-99. PMID 12700283 |
0.767 |
|
| 2003 |
Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapeutics. 2: 235-43. PMID 12657718 |
0.311 |
|
| 2003 |
Engman L, Al-Maharik N, McNaughton M, Birmingham A, Powis G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants. Anti-Cancer Drugs. 14: 153-61. PMID 12569302 DOI: 10.1097/00001813-200302000-00009 |
0.302 |
|
| 2003 |
Nonn L, Williams RR, Erickson RP, Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Molecular and Cellular Biology. 23: 916-22. PMID 12529397 DOI: 10.1128/Mcb.23.3.916-922.2003 |
0.619 |
|
| 2002 |
Husbeck B, Powis G. The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells. Carcinogenesis. 23: 1625-30. PMID 12376470 DOI: 10.1093/Carcin/23.10.1625 |
0.781 |
|
| 2002 |
Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Research. 62: 5089-95. PMID 12208766 |
0.333 |
|
| 2002 |
Husbeck B, Berggren MI, Powis G. DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences. Advances in Experimental Medicine and Biology. 500: 157-68. PMID 11764930 DOI: 10.1007/978-1-4615-0667-6_21 |
0.799 |
|
| 2001 |
Berggren MI, Husbeck B, Samulitis B, Baker AF, Gallegos A, Powis G. Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Archives of Biochemistry and Biophysics. 392: 103-9. PMID 11469800 DOI: 10.1006/Abbi.2001.2435 |
0.779 |
|
| 2001 |
Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annual Review of Biophysics and Biomolecular Structure. 30: 421-55. PMID 11441809 DOI: 10.1146/Annurev.Biophys.30.1.421 |
0.487 |
|
| 2001 |
Xie W, Peng H, Kim DI, Kunkel M, Powis G, Zalkow LH. Structure-activity relationship of aza-steroids as PI-PLC inhibitors. Bioorganic & Medicinal Chemistry. 9: 1073-83. PMID 11377165 DOI: 10.1016/S0968-0896(00)00302-3 |
0.3 |
|
| 2001 |
Rong SB, Hu Y, Enyedy I, Powis G, Meuillet EJ, Wu X, Wang R, Wang S, Kozikowski AP. Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. Journal of Medicinal Chemistry. 44: 898-908. PMID 11300871 DOI: 10.1021/Jm000493I |
0.322 |
|
| 2001 |
Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annual Review of Pharmacology and Toxicology. 41: 261-95. PMID 11264458 DOI: 10.1146/Annurev.Pharmtox.41.1.261 |
0.487 |
|
| 2001 |
Hu Y, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. 3-deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth Bioorganic and Medicinal Chemistry Letters. 11: 173-176. PMID 11206452 DOI: 10.1016/S0960-894X(00)00640-5 |
0.37 |
|
| 2000 |
Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radical Biology & Medicine. 29: 312-22. PMID 11035260 DOI: 10.1016/S0891-5849(00)00313-0 |
0.785 |
|
| 2000 |
Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. Journal of Medicinal Chemistry. 43: 3045-51. PMID 10956212 DOI: 10.1021/Jm000117Y |
0.431 |
|
| 2000 |
Freemerman AJ, Powis G. A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells. Biochemical and Biophysical Research Communications. 274: 136-41. PMID 10903908 DOI: 10.1006/BBRC.2000.3091 |
0.327 |
|
| 2000 |
Xie W, Peng H, Zalkow LH, Li YH, Zhu C, Powis G, Kunkel M. 3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity. Bioorganic & Medicinal Chemistry. 8: 699-706. PMID 10819158 DOI: 10.1016/S0968-0896(00)00014-6 |
0.345 |
|
| 2000 |
Peng H, Xie W, Kim DI, Zalkow LH, Powis G, Otterness DM, Abraham RT. Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase. Bioorganic & Medicinal Chemistry. 8: 299-306. PMID 10722152 DOI: 10.1016/S0968-0896(99)00284-9 |
0.348 |
|
| 2000 |
Baker A, Santos BD, Powis G. Redox control of caspase-3 activity by thioredoxin and other reduced proteins. Biochemical and Biophysical Research Communications. 268: 78-81. PMID 10652216 DOI: 10.1006/Bbrc.1999.1908 |
0.374 |
|
| 1999 |
Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemotherapy and Pharmacology. 44: 491-7. PMID 10550570 DOI: 10.1007/S002800051123 |
0.361 |
|
| 1999 |
Gasdaska PY, Berggren MM, Berry MJ, Powis G. Cloning, sequencing and functional expression of a novel human thioredoxin reductase. Febs Letters. 442: 105-11. PMID 9923614 DOI: 10.1016/S0014-5793(98)01638-X |
0.35 |
|
| 1999 |
Berggren MM, Mangin JF, Gasdaska JR, Powis G. Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. Biochemical Pharmacology. 57: 187-193. PMID 9890567 DOI: 10.1016/S0006-2952(98)00283-4 |
0.343 |
|
| 1998 |
Powis G, Kirkpatrick DL, Angulo M, Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chemico-Biological Interactions. 23-34. PMID 9679540 DOI: 10.1016/S0009-2797(97)00148-8 |
0.385 |
|
| 1997 |
Dvorakova K, Dorr RT, Gallegos A, McClure T, Powis G. Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice. Journal of Chromatography. B, Biomedical Sciences and Applications. 696: 275-81. PMID 9323548 DOI: 10.1016/S0378-4347(97)00261-2 |
0.314 |
|
| 1997 |
Yeates LC, Powis G. The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer Biochemical and Biophysical Research Communications. 238: 66-70. PMID 9299453 DOI: 10.1006/Bbrc.1997.7238 |
0.399 |
|
| 1996 |
Gasdaska JR, Kirkpatrick DL, Montfort W, Kuperus M, Hill SR, Berggren M, Powis G. Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73→Ser mutation Biochemical Pharmacology. 52: 1741-1747. PMID 8986137 DOI: 10.1016/S0006-2952(96)00595-3 |
0.387 |
|
| 1996 |
Weichsel A, Gasdaska JR, Powis G, Montfort WR. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure (London, England : 1993). 4: 735-51. PMID 8805557 DOI: 10.1016/S0969-2126(96)00079-2 |
0.359 |
|
| 1995 |
Brunn G, Fauq AH, Chow S, Kozikowski AP, Gallegos A, Powis G. Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity. Cancer Chemotherapy and Pharmacology. 35: 71-9. PMID 7987980 DOI: 10.1007/Bf00686287 |
0.311 |
|
| 1995 |
Powis G, Hill SR, Frew TJ, Sherrill KW. Inhibitors of phospholipid intracellular signaling as antiproliferative agents. Medicinal Research Reviews. 15: 121-38. PMID 7739293 DOI: 10.1002/Med.2610150204 |
0.373 |
|
| 1995 |
Powis G, Berggren M, Gallegos A, Frew T, Hill S, Kozikowski A, Bonjouklian R, Zalkow L, Abraham R, Ashendel C. Advances with phospholipid signalling as a target for anticancer drug development. Acta Biochimica Polonica. 42: 395-403. DOI: 10.18388/Abp.1995_4893 |
0.433 |
|
| 1990 |
Howie AF, Forrester LM, Glancey MJ, Schlager JJ, Powis G, Beckett GJ, Hayes JD, Wolf CR. Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis. 11: 451-8. PMID 2311189 DOI: 10.1093/Carcin/11.3.451 |
0.334 |
|
| 1990 |
Forrester LM, Hayes JD, Millis R, Barnes D, Harris AL, Schlager JJ, Powis G, Wolf CR. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis. 11: 2163-70. PMID 2265468 DOI: 10.1093/Carcin/11.12.2163 |
0.371 |
|
| 1985 |
Martin WJ, Powis G, Kachel DL. Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells. Journal of Laboratory and Clinical Medicine. 105: 23-29. DOI: 10.5555/Uri:Pii:0022214385900848 |
0.302 |
|
| Show low-probability matches. |